Furthermore, there was no significant difference in the comparison between anti-PD-1/PD-L1 inhibitors and biologics, whether in OS or PFS analysis, it reveals that anti-PD-1/PD-L1 inhibitors failed to provide more survival benefits than biologics, including TKI, anti-angiogenic agents and the like, which indicates anti-PD-1/PD-L1 inhibitors can be compared to a biologics in clinic so far—a an entirely new line of medical research into anti-tumor treatment, but no substitute for biologics. This evidence concerns the gene CD274 and neoplasm.